Belantamab mafodotin lyophilized powder for Multiple Myeloma

"Belantamab mafodotin lyophilized powder was initially investigated in 2015 at Weill Cornell Medicine / New york Presbyterian Hospital. To this day, there have been two concluded clinical trials and 33 are actively enrolling patients with a large proportion of these studies based out of Atlanta, Georgia."

"This research program is no longer accepting new volunteers. It was originally posted on June 18th, 2018 and ended editing in July 27th 2022. If you are looking for alternative studies, 807 clinical trials recruiting patients with multiple myeloma and 33 separate investigations into Belantamab mafodotin lyophilized powder are currently in active search of enrollees."

"Currently, there are 33 active clinical trials for Belantamab mafodotin lyophilized powder scattered across 221 urban centres and 34 countries. Karyopharm Therapeutics Inc initiated the first drug approval study in 2015 which involved 518 patients and finished its Phase 1 & 2 stages. Since then, two more have been conducted."

"Belantamab mafodotin lyophilized powder can be employed to modulate the immune system and address various medical issues including a history of proteasome inhibitor treatment, refractory multiple myeloma, or prior anti-cd38 monoclonal antibody therapy."

"Belantamab mafodotin lyophilized powder has been assessed with a score of 2 on the safety scale due to existing data supporting its relative security, though there is not yet any evidence confirming efficacy."

"Per the trial's patron, GlaxoSmithKline, the primary outcome to be monitored over a timespan of up to 48 weeks is Overall Response Rate as assessed by an Independent Review Committee (Efficacy Population). Additionally, this research will evaluate secondary outcomes such as the Number of Participants With Grade Change From Baseline in Systolic Blood Pressure and Diastolic Blood Pressure using NCI CTCAE version 4.03 grading criteria for each metric. The AUC(0-tlast) of GSK2857916 Total Antibody Following IV Dose in Participants With RRMM and Tmax of Cys-"

"This research trial is enrolling at a total of 21 sites, including Atlanta, New Haven and Chicago. To minimize travel needs, participants should select the site nearest to them for participation."

"This scientific trial has ceased patient recruitment. The study was first listed on June 18th 2018 and the page was last updated July 27th 2022. There are 807 trials recruiting individuals with multiple myeloma, as well as 33 studies actively looking for volunteers to test Belantamab mafodotin lyophilized powder."